Metropolis Healthcare Limited (METROPOLIS) Earnings Call Transcript
February 5, 2026
Earnings Call Speaker Segments
It. Ram. Sa. That. It. Sam. Good day, ladies and gentlemen, and welcome to the Q3FY26 earnings conference call for Metropolis Healthcare Limited, hosted by ICICI Securities. This call may include forward-looking statements regarding the company that rest on the beliefs, opinions, and expectations of the company as of the date of this call. Such statements do not guarantee the company's future performance. Such statements do not guarantee the company's future performance, and they may involve risks and uncertainties that are hard to predict. As a reminder, every participant line will be in listen-only mode, and you will have a chance to ask questions once the presentation ends. If you need help during this call, please signal an operator by pressing Star then zero on your touchtone four. Please be aware that this conference has been recorded. I now hand the conference over to Ms. Nisha Shetty from ICICI Securities. Thank you. And over to you ma'. Am.
Thanks, Shubham — morning.
Apologies for cutting in. Nisha, we can’t hear you.
Hello. Yes. On behalf of ICICI Securities, welcome to the Q3FY26 earnings conference call for Metropolis Healthcare Limited. We appreciate the Metropolis Healthcare management team providing us with the chance to host today's call. Joining us today are Ms. Amira Shah, Chairperson and Whole Time Director; Mr. Surendran Chemin Kotel, Managing Director; Mr. Sameer Patel, Chief Financial Officer; and Mr. Avduj Joshi, Chief Business Development Officer. I'll now turn the call over to Ms. Amira Shah for her opening remarks. Thank you. Over to you, ma'am.
Thanks, Nisha. Good morning, everyone, and thanks for being with us today on the call covering Q3 and the nine months of FY26. As noted, our team is here with me. The investor presentation and financial results are now available on the stock exchange and on our website, and I hope you've all had a chance to look through them. I'll start with a brief look at the industry landscape and our strategic priorities, and after that we'll walk through operational and financial performance for the quarter. Across the last few quarters, demand in diagnostics has stayed stable, with growth coming more and more from specialty diagnostics, preventive healthcare and complex testing instead of routine investigations on their own. Among clinicians and patients alike, awareness is steadily moving toward a stronger focus on accuracy, depth of insight and decision making driven by precision, on a global level. There's been a fair amount of discussion about tariff actions and trade policies, especially from the US. Still, we want to make clear that healthcare and diagnostics is mostly domestic in nature, with sourcing and service delivery localized, and it stays largely neutral to these developments, and right now we don't foresee any material impact on our operations or cost structures.
The union budget that was announced recently makes it obvious that healthcare is a top priority, covering pharma, hospitals, diagnostics and allied services. There is a heavy emphasis on building the workforce — upgrading allied health institutions that already exist and establishing new ones in both the public and private sectors — with the goal of adding close to 100,000 professionals across 10 disciplines within five years, which will bolster diagnostic and clinical capacity. Tier 2 and regional healthcare infrastructure also get attention in the budget, and that ought to cut down how many patients travel to metro cities while improving access for underserved populations. All in all, it cements a long-term policy commitment to broadening access, capacity and quality in healthcare throughout the value chain. For a healthcare leader such as Metropolis, this opens up opportunities that were not there before, particularly in India's smaller markets. Inside India, diagnostics is slowly moving into a consolidation phase. The period of irrational capital and weak unit economics appears to be finished, and consolidation has returned. Financial and strategic capital is now looking for bigger acquisitions, with greater weight on long-term growth and solid economics instead of revenue growth driven by discounts. Against this backdrop, Metropolis is well placed, thanks to our strong brand recall with doctors and consumers, our scientific leadership, and a Pan India network of labs and collection centers.
We still think our moat is strong, thanks to a trusted brand, quality processes and scaled infrastructure, and we keep looking for acquisitions that are high quality and reasonably priced. One key milestone this quarter was opening our center of Genomics in Delhi after integrating CodyGoft, which now serves as the national reference hub for advanced molecular testing and precision diagnostics, backed by our CAP accredited laboratories in Gurgaon and Bombay. As an integrated platform, this center of Genomics combines high throughput sequencing, advanced bioinformatics and robust clinical interpretation capabilities, which lets us deliver clinically actionable genomic insights at scale across oncology, reproductive health, inherited disorders and preventive genomics. This test category is expanding quickly in the industry and at Metropolis. We believe we are developing the capabilities to become very significant players in this category. It will be a key strategic growth lever over the next few years, generating business via B2C and B2B — a test category that demands precision experience, interpretation by experts and a broad network of centers, which fits perfectly into Metropolis Right to win. Beyond genomics, we keep advancing our digital and AI journey in a measured and responsible way.
AI and pathology clearly hold a lot of promise, but we think meaningful clinical adoption is still at an early stage. So our focus stays on selective, high impact use cases instead of broad based deployment. Right now, at Metropolis, AI is being used in a few targeted areas, including enhanced depth interpretation, strengthening quality monitoring, supporting scientific selling and enhancing customer conversion. At the same time, we are actively working on a pipeline of future applications across support interpretation, clinical decision support, workflow optimization and automating certain processes. Over the medium to long term, we believe AI will play an important role in improving productivity and report on around time and strengthening quality governance and pathology. AI can play an enabling role to improve productivity and analytics, but at this time it is unlikely to replace doctors or disrupt the industry cost structure overnight. As part of our science led innovation journey, we achieved an important milestone this quarter with the grant of our first patent by the Patent Office of the Government of India for a system focused on monitoring and managing TB related infections. To our knowledge, this makes Metropolis one of the first listed diagnostic companies in India to receive a patent of this nature, reflecting our commitment to scientific research and clinical innovation.
Bringing in this tool could let us engage more meaningfully with the physician who prescribes, with people receiving TB treatment, and support them through diagnosis and care. Turning to the inorganic side, the acquisitions we completed recently are moving along nicely and have been folded into the Metropolis system effectively. Within core diagnostics, our main emphasis across recent quarters has centered on aligning operations, standardizing processes, and capturing cost synergy. We had anticipated coal margins in Q3 would come in somewhat above Q2, since the plan called for rolling out the Genomics platform during Q3 25, which would have delivered better gross margins on those genomics tests. Because machine arrival into India was delayed, though, the launch happened 3 months later, on January 26th, and so those tests were outsourced at thinner gross margins in the earlier period, which pulled ebitda down. As of January 26th, however, these tests are now running in house, and for Q4 we anticipate a substantial gross margin gain that supports a high single digit EBITDA margin for core during Q4 of this year. The smaller acquisitions we made — Dehradun, Agra and Kolhapur among them — keep delivering in line with expectations, with margins exceeding the group average overall. As we close out the year, we expect our acquisition portfolio to show clear synergy gains spanning revenue growth, an improved test mix, and channel diversification.
As we look forward, the fourth quarter tends to be a seasonally stronger period for diagnostics companies. Although seasonal patterns have grown less predictable since Covid, we are entering the quarter with encouraging momentum — sustained traction across channels, improving productivity and a better mix. We stay confident about meeting our guidance of 12 to 13% organic growth and expanded margins for FY26, along with a gradual uptick in margins driven by scale and operational efficiencies, material productivity and prudent cost management. To conclude, Metropolis remains firmly committed to building a high quality, science led diagnostics platform anchored in accuracy, consistency and clinical trust. With disciplined strategy execution and strong operational leadership, we believe we are well positioned to deliver sustained long term value for all stakeholders. Finally, the Company is pleased to inform its shareholders that the Board of Directors has approved a bonus share issue in the ratio of 3:1, i.e. three fully paid up equity shares of face value rupees two each for every one existing equity share, subject to the necessary statutory and shareholder approvals. This bonus issue, made by capitalizing a part of the Company’s reserves, reflects the Company’s strong financial position and continued confidence in its long term growth prospects.
The goal here is to reward shareholders for their ongoing support and at the same time make the Company’s equity shares more liquid in the market. With that said, I’ll hand things over to Suren, who will take you through how operations performed and what drove the business during the quarter.
Thanks, Amira, and good morning, everyone. We're happy to share that quarter three was a strong one: group revenues rose 26% compared with a year earlier, and for the nine months revenues were up 24 percentage on a year-on-year basis. Organic revenue growth stayed healthy, at 15 percentage for the quarter and 13 percentage for the nine months, backed by balanced volume expansion, an improving test mix, and disciplined execution throughout our businesses. What stands out as especially encouraging this quarter is how performance came through across the board — segment geographies, patient volumes, and margins. For the diagnostics industry, Q3 is usually a softer quarter seasonally, because of festive holidays, fewer outpatient visits, and a lower number of elective procedures. On top of that, this year we saw atypical seasonal behavior in quarter two, since the infection-led diagnostic demand we normally expect did not come through as anticipated. Seeing those early trends, we proactively recalibrated where we put our operating focus, stepping up efforts to build a high-quality B2B and institutional business so that we would enter quarter three with a stronger, more stable, and more predictable demand base. That strategic pivot helped us keep our growth momentum going even without seasonal tailwinds, and to deliver balanced performance across both B2C and B2B segments. Over the past year I've talked about our work on a structured cleanup of lower-quality institutional accounts — exiting businesses that diluted margins, ran inefficiently operationally, or did not align with our service and quality standards.
Over the course of this year, we've deliberately assembled a higher-quality pipeline of partnerships across institutions and corporations, placing sharper emphasis on clinical engagement, service excellence, and unit economics that hold up over time. That revised approach to the institutional side of the business has now begun producing concrete outcomes, adding meaningfully to how we performed in quarter three and lifting the overall quality of our revenue mix. Organically, revenue was up 15 percentage year on year, backed by healthy growth in patient volume of 9% year on year. Within the B2C segment, which accounted for roughly 60% of our revenues, revenue rose 15%, propelled by strong results in truhealth and specialty. Truhealth kept scaling nicely, supported by curated wellness packages, rising adoption of prevending health, and deeper engagement on digital channels. Specialty testing posted robust growth thanks to focused clinician engagement, scientific upselling, and wider deployment. Of advanced tests across centers. Crucially, bringing code diagnostic into the fold has started to meaningfully strengthen our specialty portfolio, letting us cross sell super speciality and advanced oncology test into the wider metropolis, customer base and clinician network. This cross selling, and the capabilities it leverages, is reinforcing our leadership in complex diagnostic and building a sustainable pipeline for growth in higher value. Test in the B2B segment, which made up 40% of revenues, 15% year on year growth came from both expansion in volume and better realization.
We strengthened ties with major institutional clients, labs and hospitals by assigning dedicated account managers, cutting turnaround times and lifting service quality. Specialty testing in B2B showed strong momentum, which reflects clinicians' growing confidence in our advanced diagnostic capabilities. Our corporate business was especially important in steadying results this quarter, since it brought predictable volumes, healthier realizations and a more resilient revenue base. On geography, our continued push into Tier 2 and Tier 3 markets keeps producing strong results. Across the last two years we have methodically widened our footprint in cities and towns, creating a hub and spoke network that supports efficient scaling. In this quarter we opened 110 new centers, the bulk of them via the franchisee route, bringing total additions to over 300 centers across nine months and boosting our presence to 750 towns. That network build-out is now feeding through into consistent volume growth, better asset utilization and operating leverage on margins for the organic business. We turned in a strong performance this year, with a healthy 29.3% year on year expansion of EBITDA margins, which stayed robust at roughly 25 percentage. The gain came from a mix of material cost efficiencies, operating leverage on fixed costs and ongoing productivity efforts throughout the network.
Disciplined cost management, smarter procurement and more efficient workflows keep driving structural gains in margin. There was also a one-time hit this quarter from implementing the labor code — roughly 9 crores at the group level — which will weigh on profitability. Apart from that, the underlying performance stayed very strong, which reinforces both the quality and the sustainability of our earnings. Quality remains the cornerstone of how we operate. Early this year we introduced the Internal Quality Control Index, a science-based performance framework built to set uniform, measurable, real-time quality benchmarks across the whole laboratory network. That framework follows the entire diagnostic journey — from pre-analytics and logistics through laboratory examination to post-analytical reporting — using rigorous clinical and operational parameters. It allows us to spot deviations early, take corrective action quickly and keep diagnostic accuracy consistent across geographies. At the same time, we keep watching pre-analytical compliance at every collection center and logistics touch point, which strengthens sample integrity and chain of custody before samples even reach the lab. Taken together, this work has meaningfully improved governance, transparency and clinical reliability throughout our growing network. As we look toward quarter four, early momentum across channels is encouraging, along with favorable continued traction in specialty and wellness, a wider network reach and ongoing productivity gains.
We're still confident that we'll finish the year on a very strong note, consistent with our growth and margin objectives. In closing, quarter three shows the strength of our operating model, which brings together strategic agility, scientific leadership, disciplined execution and quality governance. We're well positioned to keep up the momentum and deliver long-term value creation. With that, I'll now hand things over to Samir Patel, our Chief Financial Officer, to take you through the financial performance. Thank you.
Thank you, Suresh. Good morning, everyone. I'd like to walk you through some of the key financial results for fiscal 3 FY26. As we communicated last quarter, we've split how we report performance across two dimensions. For this year, the Amateur group takes in four acquisitions — Core Diagnostic Scientific Pathology, AGRA, and Ambigua Diagnostic Kolhapur. MHL Organic leaves those four acquisitions out. Now, turning to the financial and operating results, I'll start by calling out operational performance for MHL on an organic basis. Revenue and EBITDA rose 15% and 29%, respectively, but once you exclude the exception item, the increase was 52% year on year. Patient volumes came in at 3.3 million, up 9% year on year. Test volumes reached 7 million, an 8% increase year on year. With a growing contribution from TRU Health and the specialty segment, both our B2C and B2B revenue were up 15% year over year. The 2 health and specialty segments each grew 25% and 16%, respectively, year on year. B2C revenue made up 60% of total revenue; within the B2C segment, revenue for specialty and 2 health climbed 17% and 29%, respectively, year on year. B2B revenue accounts for 40% of total revenue, and the B2B specialty group was up 16% year on year.
EBITDA came in at rupees 93 crore, which represents 29.3% growth year on year. The EBITDA margin was 25%, up two hundred and eighty basis points compared with the same period a year earlier. PAT, excluding exception items, was 48 crore. That's 52% growth year on year. The impact of the labor code, amounting to 8 crore, has been treated as an exception item. Margins excluding exception items rose to 12.8%, an increase of 300 basis points. Second, on the key performance indicators for the MHL group: revenue was up 26% year on year, patient volume came to 3.5 million, and test volume was 7.3 million. Those represent growth of 14% and 13% respectively year on year. B2C and B2B revenue grew 19% and 35% respectively year on year. At the MHL group level, the north now accounts for 17% of overall revenue, largely as a result of recent integrations that have a major presence and revenue coming from the northern region. EBITDA margin was 23.4%. The decline relative to the organic business was largely due to the lower margin profile of code compared with the margin for code edmids, which is expected to meet the stated guidelines of high single digit as an exit run rate for Q4FY26, with type excluding exception items at 251 crore.
We achieved 63% growth on a year-over-year basis. The impact from the labor code, which comes to Rupees nine crore, is being treated as an exception item at the group level. Margin excluding that exception item came in at 12.6%, which is an increase of 280 basis points. For the year, estimated capex is rupees 55 to 60 crore. This spending is mainly directed toward strengthening and expanding our Pan India network, operating IT systems and processes, and scaling up high end equipment to support advanced and super specialty test capabilities. Turning to liquidity, our position and cash strength, the company remains net debt free, with current cash reserves of rupees 127 crore. We will keep accumulating cash in order to fund and support our future growth initiatives. That’s all from my side. With this, I open the floor for question and answers.
Thanks so much. We're going to move into the question-and-answer portion now. If you'd like to pose a question, you can press Star and one on your Touchstone phone. Should you want to take yourself out of the queue, just press star and 2. We ask that participants use answers when asking a question. Ladies and gentlemen, we'll pause briefly while the queue is put together. Our first question is from Surya Narayan Pathra at Philip Capital India. Please go ahead.
Thanks for taking the question. First thing I'd like to ask about is the — could you share what organic volume growth we would have recorded at the test site?
Organic Test. For this year, heading into this quarter, volume growth stands at 8 percentage.
All right, thanks for that. My second question concerns the genomic initiative. We've brought in additional equipment and broadened the capability in that area, and we also view this as a valuable growth driver going forward. That said, right now we're aware that genomics has never really been a high-volume growth segment in India up to this point, and competition is heating up on that front as well, with talk of disruptive pricing. So what's your thinking here, and how do you expect this opportunity to add incrementally in value terms?
Thanks. Look, when you consider how Metropolis is positioned, we’ve really never been the kind of company that concentrates on tests that have become commoditized at high volume. Our focus has been on ensuring that every area where we’re genuinely active is a non-commoditized space—one that’s truly centered on delivering the right report to the patient at the moment it’s needed in the clinical setting. In genomics, if you look at the therapeutic areas that are expanding most rapidly worldwide, they’re actually oncology and neurology across the coming 10 years, and the same situation is going to be in India, both for cancer and for any brain or nervous system areas. Ultimately, the most important tests are going to be genomics. So we expect this category to grow very fast over the next ten odd years and longer. And therefore being a critical player in that market is important, and the business that comes—you know, there are, you’re right, there are at least 7, 8 players in the space. But it’s only 7, 8 compared to, you know, all the other tests where you have 3 lakh players. So comparatively you’re talking about still this being a cohort which has lesser competition.
And even among the 7, 8, or 10, 15 players involved in genomics, we have to keep in mind that doctors will require the highest-quality, most precise reports — and that is exactly where Metropolis's positioning will remain. And we're seeing that our uptake of genomics has been very rapid ever since we launched them.
Alright, thanks for that. The next question concerns how large the network expansion will be. It's also generally thought that there's a sort of mentor involved. Now, Metropolis is clearly concentrating more on putting the asset in place after building a strong network expansion across recent years. But that's why there's a kind of model, and moderation in that model, on the network addition front that we've seen. Yet at the same time, that's also regarded as a kind of key growth driver. So given that, what's your thinking for the period ahead?
As I say, we've brought this up before. Also, in the past, the lab expansions have largely been carried out mainly to serve the 750 towns we're now concentrating on. The emphasis is on penetrating deeper into those 750 towns and on upgrading and strengthening the customer service network in place there, and mostly by way of the franchise channel. So that's what we've been doing over the last 2, 3/4, and we'll carry on with it, and we see ample and then some opportunity to grow our network further across these 750 towns, and we'll keep at this and generate additional volumes and revenue growth from the tier 3, tier 4 type of cities.
Alright, just one final point from me, sir. As we also saw in the opening remarks, you mentioned — ma’am — that there’s a somewhat volatile situation when it comes to currency, when it comes to trade issues, everything we’ve witnessed. So even though this industry is immune from all of that, since it is a domestic one, is there any impact that one should anticipate on reagent cost and the like?
At this moment, we aren't expecting anything. But look, I mean, if the rupee goes wild in a big way, you know, there's always obviously a possibility that vendors could return and, you know, possibly bring up renegotiation. That said, a lot of reagents and vendors are actually based more in the EU and maybe even some in Japan, and fewer, I'd say, in the US. So I don't see too much exposure right now.
Yes, thanks a lot.
Appreciate it.
Thanks. Just a quick reminder for everyone: if you'd like to ask something, you can hit star and one on your Touchstone phone. Our next question is from Sudarshan Agarwal at Access Capital. Go ahead.
Congrats on the strong results. I was looking at that data point where you mention you've kind of closed down during this quarter. Could you tell me whether that relates to the core of the recent acquisitions, what drove that close down, and whether any further closures are expected in the quarters ahead?
I mean, essentially every lab we've shut down over the past two quarters has mainly been due to integration. Any time a town has two labs that overlap, we've simply chosen to keep just one of them. That has been our stated strategy all along. There are also a few additional labs we might close in quarter four. By the time this year ends, the count could be somewhat lower than where we're beginning the quarter. Right. So expect perhaps two or three more labs to be integrated.
Understood. On your volume growth, it has, as you guided, been improving, and it came in at roughly 8 odd percent. Q4 is the near term. Over the longer term, though, do you expect that mid to high single digit patient volume growth to be sustained?
So 7 to 8 percentage volume growth — that's always been what we aspire to in the near future, and we're working toward it. We've begun to see early successes on our programs, and we still believe that 7 to 8 percentage is the range we can hit in the days to come.
Understood. And finally, on core diagnostics, because of how these tests work, I’d assume there’s a smaller seasonal component tied to those oncogenomic tests. Right. So based on certain assumptions I’ve made, I think we would have seen a sharper sequential decline in core. What caused these—I understand there was some delay with machines and so on—but a sequential revenue decline did occur. Is that correct?
Nothing more pronounced than that. As you were just saying, there's a minor decline, since during quarter three, typically on account of the festive period and so on, the processes grind to a stop and then pick up again in quarter four. So a very slight decrease in quarter three. Still, I'd say we're seeing quarter four return at full strength.
That covers everything I had. Thanks.
Thanks.
Thanks. Our following question is from Sriram Srivasan at Goldman Sachs. You have the floor.
Good morning, and thanks for taking my question. First, on the GST impact from a pricing angle in Q3 or perhaps Q4: given all the reagent GST reductions, does anything change in how this plays out for us? Is it already reflected in our RPP for Q3, or should we expect realization to shift in Q4?
Look, the GST effect on us is really quite marginal. What actually took place, if you've been watching it, is that the GST on materials going into diagnostics stood at roughly 12 percentage and has now gone up to 5 percentage. And a number of the reagents are already sitting at 5 percentage, while some of them were at 12, 18% and have now come down to 5 percentage. So we do get a marginal benefit that flows through into our, you know, results. But if you're also aware, you know, that every year in January we would carry out a price revision. So this year we've pushed the price revision back and it didn't take place in January. Essentially so that at least, you know, customers keep getting the benefits of these revisions.
Understood. I want to revisit the price change, since that ties into your second question. Does the current environment support raising prices? Looking at it from a competition angle, yes. Even though the GST savings have to be handed over, do you see a new timeline for when you might take another look at your own pricing?
Right, we do see that the market can definitely perhaps take some price increase, and conditions are favorable, but we're putting it off and delaying it for the reasons I already gave. I mean, when exactly will we do it? That's still a call we have to make. We'll keep watching the market for a while longer, and then at the right moment we'll make use of the price tables too.
Thanks, that's really useful. Just one last question — it's about how you think, over the medium term, regarding guidance for the top line only. If you can deliver 7%, 6%, 7% — I'm simply taking patient volume at 6%, 7%; somehow test volume and patient volume look like the same figure for you, similar figures — and then you add RPP of 5%, 6%, you know, and then there's mix change. Let's assume that, which I'm certain should show up in RPP. Why can't we grow at a pace beyond the 12% to 13%?
So, as you can see, we achieved 15% growth in quarter three. Right. And going forward, of course, you can look for better top-line performance.
At some point, possibly during Q4, when you provide guidance for fiscal 27 — perhaps, you know — that's the moment you'll lay out what growth you plan for the following year.
Right, so the projection for this year came in at 12 to 13 percentage, and we'd obviously prefer to land at the top of that 12 to 13 percentage range we've been referencing, and so, you know, you'll notice a comparable pattern in quarter four too.
Appreciate it. Wishing you all the best.
Thank you. One quick note for everyone on the call: if you'd like to pose a question, just hit star, and if you're joining by telephone, our next question will come from Lokesh Manik at Valium Capital. Go right ahead.
Yes. Hello, good morning ma’am and team members. I have a couple of questions. Mayank, from my side, one concerns routine testing — you have recorded 12% growth. Your industry peers, you know, have actually registered a decline in that segment. So would that be put down to, you know, the geography where we operate, or would you put it down to our approach of concentrating more on volume, which has been our approach over the last three to four Quarters, or maybe months.
Look at routine and semi-special. Actually, every test volume by category that we listed in the investor deck is on a consolidated basis. Right. So the figure you're looking at for routine and semi-special, a 15, 16 percentage growth in quarter three, takes in all the new entities we brought in during this year.
Yes. So even in organic, we've seen growth. 12%, if I'm not mistaken.
When we look at organic, volume is up 8% in testing. What I’m referring to is revenue growth — specifically, the revenue for that segment that we—
I guess my question is whether geography is the factor behind it—since we’re located in western India, is that what’s driving this—or is it more of a focus strategy?
Not really. What I mean is, ultimately what matters is how well you execute. So it isn’t really about geography — in fact, if you look at it, the north is likely our fastest-growing region. So I’d say it comes down to the strategy and how you carry it out.
12% is the standard rate, while 9% is the semi-special one.
Got it. This came about because peers were underperforming, you know? So I figured maybe I just wanted clarity on where it originated. That is, one second — it's the GLT test, the GLT drugs that are losing patent protection. So do we have a focused strategy in place to, you know, capitalize on the testing requirements that are going to arise as a result of this, or do we think that, you know, those requirements are largely already met by the existing test menu we're offering?
Look, every one of the GLP therapies hitting the market is going to need baseline testing to determine what's going on inside the body so dosage can be moderated, plus ongoing monitoring to check whether it's genuinely working and not causing any harm to the body. So what we expect is that, just like with any other drug, if people are going to take medicines, they're going to have to monitor their blood levels as the underlying effect. So naturally, with GLP arriving in a big way, we do expect our GLP packages, along with all the other products we've launched, to pick up in a fairly bigger way. And we've already launched all of these GLP fund packages.
That's all I have to share. Thank you very much.
Thank you. Ladies and gentlemen. Should you want to pose a question, you can press Star and one on your Touchstone phone. Our next question is from the line of. From bmspn, please go ahead.
Yeah, hi. So I keep, I keep seeing some kind of rumor that keeps circulating on WhatsApp. About Reliance getting into the Genomics field and, you know, charging very low rates for testing. So how is this, how strong are these rumors? Could you talk about what you're hearing on the ground and how this affects your genomics business, if at all?
Honestly, it's hard to say much about their strategy or what exactly they're up to. But a genomics business already existed and it was struggling, and then they bought it from, I believe, nclt — and I'm not sure where it stands now, since clearly they aren't operating in the broader pathology arena. What we've been told, though, is that this leans more toward a data strategy, one that's more D2C and more of a screening test rather than a diagnostic test. Here's the distinction between the two: with a screening test you can go ahead and do it, but no real decision can be made unless it's a diagnostic test, since that one is more confirmatory, whereas a screening test just hands you some information and there isn't really any action you can take on it. So. Of course, only time will tell which direction this heads in. Metropolis, I'd say, is positioned very differently — we're entirely in the diagnostics space, meaning we collaborate very closely with prescribing doctors on very complex diseases, telling them: look, this is definitely what's going on in the genome, in the body, and so this is the action you can take as a result. So, two different strategies.
To draw a comparison, plenty of companies run wellness screening programs, and those can offer a rough sense of what's going on inside your body, but they don't really let you make a decision from them. A Metropolis result, by contrast, gives you definitive findings you can actually act on.
Got it? Got it. Excellent. Thanks for clarifying that. And I have just one further question regarding the labor code. You know, I keep attempting to figure out what might unfold over the coming 10 years — clearly across a really extended stretch of time — that could bring competition down. So clearly government regulation is one area where I don't believe much has taken place. Tell me if I'm mistaken, but even the labor court functions as a kind of government regulation. So do you view that as a potential catalyst for reducing competition in some way.
I mean, look — with the government bringing in stronger regulatory frameworks, whether that's on the wage code or on the quality framework, that will certainly help bring structure to the unorganized sector, obviously. But it hinges on enforcement, and it hinges on, you know, whether rules are actually followed on the ground in the unorganized sector. By the way, we're also seeing something for the first time in a long while, I would say. We're seeing the government really intent on creating deregulation and appropriate regulation across multiple sectors in the country, healthcare included, and an intent to provide some kind of compliance framework focused not just on access and affordability but on quality care as well. So I'm actually quite hopeful that we may actually see this sector begin to organize in a better way than what I've witnessed over the last 20 years.
I agree. Here's hoping that comes to pass.
Thanks.
Thanks. Just a note for everyone—if you'd like to ask something, press star then one. Our next question is from Toshit Sheikh at BNP Pariva. Go ahead, please.
Thank you for the chance to speak. Ma'am, could you possibly provide the organic revenue growth for the nine months from northern India? The point is simply to get a sense of whether Metropolis's positioning has shifted following the acquisition. In the northern market — primarily the B2C market.
Sure — so for us, the northern region of the country is expanding at a quicker pace than, you know, the other parts. And I think what we've done is essentially translate that into the contribution, which has risen from 9 percentage to 17 percentage. Right. Over the last three quarters following those acquisitions.
That would also take in a co-diagnostic.
Got it.
It would be helpful if you could call out the organic revenue growth in that area.
Well, right now I can’t provide you with the specifics, but I can tell you this: it’s expanding at a quicker pace than the company’s revenue growth.
Appreciate it.
Thanks. If you'd like to ask a question, you can press start on a touch-tone phone. Our next question is from Anshul Agarwal at MK Global. Please go ahead.
Hello, and thanks for giving me the chance to speak. I hope you can hear me clearly.
Yes.
Thanks. The first question concerns organic margins. From what I understand, during the nine-month period our organic margins widened by roughly 100bps. If I remember correctly, that was a target we had set out. Have any tailwinds from GST and similar factors contributed to this expansion? Or should we expect that kind of 100 basis point margin improvement to keep going as our lab network matures?
Sachul, I've already said this — you know the GST effect is quite marginal, and the margin expansion comes mainly from material productivity gains plus the other productivity efforts the organization has undertaken. At the start of the year we estimated 70 to 100 bps of margin improvement, and we're sticking with that. You should see that showing up in the next quarter as well.
The next question concerned our move into radiology—could you say anything about how that effort is taking shape, and do we have any plans to get into advanced radiology, even just on a pilot basis?
So I'd say we're really looking at two areas here. The first is the low-end radiology segment and how we might be able to scale that up. As we mentioned earlier, we've already made some progress on that over this past year — at this point a fair number of our centers definitely have ECG, and in some cases also X ray and sonography. And we'll keep scaling that up. There are, you know, multiple opportunities we believe can be leveraged through that model. On the high-end radiology side, we're certainly exploring whether we can pilot a couple of centers and see what kind of results we get. The idea, obviously, would be to leverage our very strong brand with doctors and with consumers, along with a reputation for technical excellence and very good customer service. So we'll certainly look at whether we can pilot something and then review the results before we scale up.
Understood — thanks. My third question concerns preventive healthcare testing within our business, where results have been very strong. Could you help me make sense of this? From what I gather, although online players essentially built this market even for organized players, on the pricing side, preventive packages offered by organized players — ourselves included — sit somewhat, or meaningfully, above those online competitors. In your view, what is fueling growth in this segment? Is it greater maturity among the broader population? What exactly do you see as the driver behind this expansion in preventive testing for organized health as well as metropolitan?
Three points. As I believe we've said before, and I'll say again, three factors are driving the preventive side — that is, wellness and the growth of bundle packages. The first is significantly greater awareness, which we as an industry are capable of building. We can build far better awareness. And second, affordability of getting these preventive checkups done — the need to get them done — is also improving. And in our own situation in particular, our capacity to, I mean, connect with our customer base through a regular baseline customer lifecycle management process and digital channels and so on is improving. So with all of that together, I think what we're seeing is, you know, the true health portfolios growing, you know, each and every.
To build on that point — in healthcare, we often see that, as you mentioned, although the market came about through the digital health tech companies, ultimately trust matters most, meaning consumer trust. And even with that market creation having happened, I'd say those who likely gained more are the incumbents, where brand trust already existed between the consumer and the institution. Then, of course, it hinges on how you execute that and whether you can capture that market creation.
Just to follow up on that point. So based on what I can gather from your comments, pricing isn't, or probably isn't, the main factor in determining which customers choose, or which diagnostic player they pick from. In preventive healthcare. Would that be a fair assumption to make?
Well, look, I think — no, I wouldn't say price isn't a significant factor when it comes to preventive healthcare. In illness and curative healthcare, I think it's definitely not a significant factor. But with preventive healthcare, I'd say it remains a significant factor, though it isn't the sole one. We need to keep in mind that at the end of the day, if someone is purchasing something, they still have to have trust in what they get out of it. So the quality of it, whether the doctor accepts it, the convenience, the experience you go through — all of these are very important as well. The interpretation you're given — is there a doctor doing a consultation with you at the end of it? These all matter a great deal in how people select a wellness package too. Price is one of them, but definitely not the only factor, and not the most important one.
And Anshul, we generated quite a bit of value as well within the overall healthcheck packages across the last 3, 4 quarters. ECG has been added, we've brought in vitals checking, and doctor consultation was introduced inside Metropolis. So customers do see value in all of these, and because of that, repeatability and all of that is improving.
I’ve got just one final book-review question for you. Could you help us get a handle on the capex figure for the nine-month period?
We're at roughly 40 crores for the nine-month period at the group level, and on a full-year basis, we figure that number lands somewhere near 60 crores.
Great. That covers everything on my side. Many thanks for your responses.
Thanks. Our next question is from Tanya Chaudhary with investech. Please go ahead.
Hello there. Hello, Akash. My question is directed at Amira. Amira, in a previous interview, you mentioned that specialty testing — particularly genomics right now — is a high-value test, but it won't be margin accretive. Still, it will raise EBITDA per patient. So I just wanted to get a sense of, you know, some clarity on the margin-accretive nature of this, and whether — if it isn't margin accretive — whether our cost efforts and other synergies will help us push margins higher. Thank you.
Thanks for asking. Let me make clear what I mean by margin accretive, or higher EBITDA today: when you look at the organization's group margin, it's close to about 25% on the MHL organic business. Right. And if the question is whether genomics margin on an individual standalone test is going to be higher than that, maybe at this point? No. The reason is that gross margins on these super specialized tests come in lower than they do on the routine test. Having said that. But if an existing customer who's already coming to you for certain tests, or comes to you with a bundle of tests, some routine along with a genomics test, then that additional EBITDA it adds to your sample is quite. So I think the way we have to look at it is whether you're picking up a single genomic sample on its own or picking it up as a battery of tests, which includes genomics. And if you're picking it up as a battery of tests, largely the majority, it will still give you a margin accretion versus picking up only a genomics test alone, because the tests are different.
Hopefully, that makes things clearer.
Right, that’s it, ma’. Am. Thanks a lot for clearing that up.
Thanks. Our next question is from Naman Bhagaricha at IFL Capital. Go ahead, please.
Hello, and thanks for the chance to ask. Just a couple of specific questions. When you look at the labor force charges, there’s an impact of roughly 2.3 bids, and at least part of that would be recurring in nature. On a recurring basis.
On a recurring basis, the amount I turned would be roughly 5 to 6 crores — no more than that.
Also, could you share the APEX guidance? My understanding was that we aimed to raise the CQ-per-lab ratio from roughly 20 to 22 — labs, 2022 collection centers per lab — up to about 30. So when do we expect that to happen? When do we expect it?
Well, I mean, that's a goal we're aspiring to. I already framed it that way. Right. And also, the count of labs being consolidated is rising while the centers increase. This is a gradual process, and you know, it's really hard for me to say when you'll reach that figure of 30. And I also think it simply doesn't matter when you get there, so long as you keep moving in the right direction.
Is there any capex guidance you'd be willing to share for the next few years?
At this point, no. We know, and perhaps down the road we’ll be in a position to share that with you.
Thanks.
Thanks, ladies and gentlemen. That wraps up the questions for today. At this point I'll pass the conference back to management for some closing remarks. Thank you. And sir, over to you.
Thanks for being with us on this Q3 call. As the team makes clear, we're feeling very strong and confident about where we're headed and about the commitments we made to our investors and shareholders at the start of the year regarding margin expansion and overall revenue growth guidance. I think we've demonstrated that over the first nine months, and we're continuing to see it in Q4 as well. We're very excited about the year ahead, and we hope that when Q4 wraps up we'll be in a position to share a strategic plan and guidance for next year too. And I think the market remains strong, and Metropolis continues to hold a leadership position. So thanks to all of you for joining, and we look forward to speaking soon.
Appreciate it from all of us here at ICICI Securities. That brings the conference to a close. Thanks for being with us — you're welcome to disconnect your microphone at this point. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Metropolis Healthcare Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Metropolis Healthcare Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.